中华老年医学杂志
中華老年醫學雜誌
중화노년의학잡지
Chinese Journal of Geriatrics
2011年
10期
830-832
,共3页
朱莉%阮中宝%殷屹岗%王如珠%林杰%任寅%陈铭%王斌%陈各才%高琳琳%朱俊国
硃莉%阮中寶%慇屹崗%王如珠%林傑%任寅%陳銘%王斌%陳各纔%高琳琳%硃俊國
주리%원중보%은흘강%왕여주%림걸%임인%진명%왕빈%진각재%고림림%주준국
前列腺素E1%冠心病%糖尿病,2型%造影剂
前列腺素E1%冠心病%糖尿病,2型%造影劑
전렬선소E1%관심병%당뇨병,2형%조영제
Prostaglandin E1%Coronary disease%Diabetes mellitus,type 2%Contrast media
目的 探讨脂质体携载前列腺素E1(PGE1)对冠心病合并糖尿病的患者发生造影剂肾病的预防作用.方法 选取行冠脉造影或介入治疗的合并糖尿病的冠心病患者198例,随机分为对照组和PGE1组.PGE1组在常规治疗的基础上予PGE1 20μg+生理盐水20ml静脉注射,1次/d,共10 d,比较两组造影前、造影后48 h、5d血肌酐(Scr)、尿素(BUN)、胱抑素C(CysC)水平及造影剂肾病发生率等.结果 造影后48 h、5dScr、BUN、Cys C等在PGE1组分别为(113.92±54.89)μmmol/L、(7.85±4.05)mmol/L、(1.38±0.34)mg/L和(86.72±35.26)μmmol/L、(6.61±3.09 )mmol/L、(1.29±0.29)mg/L优于对照组(129.22±50.18)μmmol/L、(9.26±3.95) mmol/L、(1.56±0.23)mg/L和(109.83±31.76)μmmol/L、(8.07±3.11)mmol/L、(1.37±0.21)mg/L,差异有统计学意义(均P＜0.05).经直线相关分析,造影剂剂量与BUN、Scr呈显著正相关(r=0.74,P＜0.05; r=0.82,P＜0.01).结论 PGE1对冠心病合并糖尿病的患者发生造影剂肾病有预防作用.
目的 探討脂質體攜載前列腺素E1(PGE1)對冠心病閤併糖尿病的患者髮生造影劑腎病的預防作用.方法 選取行冠脈造影或介入治療的閤併糖尿病的冠心病患者198例,隨機分為對照組和PGE1組.PGE1組在常規治療的基礎上予PGE1 20μg+生理鹽水20ml靜脈註射,1次/d,共10 d,比較兩組造影前、造影後48 h、5d血肌酐(Scr)、尿素(BUN)、胱抑素C(CysC)水平及造影劑腎病髮生率等.結果 造影後48 h、5dScr、BUN、Cys C等在PGE1組分彆為(113.92±54.89)μmmol/L、(7.85±4.05)mmol/L、(1.38±0.34)mg/L和(86.72±35.26)μmmol/L、(6.61±3.09 )mmol/L、(1.29±0.29)mg/L優于對照組(129.22±50.18)μmmol/L、(9.26±3.95) mmol/L、(1.56±0.23)mg/L和(109.83±31.76)μmmol/L、(8.07±3.11)mmol/L、(1.37±0.21)mg/L,差異有統計學意義(均P＜0.05).經直線相關分析,造影劑劑量與BUN、Scr呈顯著正相關(r=0.74,P＜0.05; r=0.82,P＜0.01).結論 PGE1對冠心病閤併糖尿病的患者髮生造影劑腎病有預防作用.
목적 탐토지질체휴재전렬선소E1(PGE1)대관심병합병당뇨병적환자발생조영제신병적예방작용.방법 선취행관맥조영혹개입치료적합병당뇨병적관심병환자198례,수궤분위대조조화PGE1조.PGE1조재상규치료적기출상여PGE1 20μg+생리염수20ml정맥주사,1차/d,공10 d,비교량조조영전、조영후48 h、5d혈기항(Scr)、뇨소(BUN)、광억소C(CysC)수평급조영제신병발생솔등.결과 조영후48 h、5dScr、BUN、Cys C등재PGE1조분별위(113.92±54.89)μmmol/L、(7.85±4.05)mmol/L、(1.38±0.34)mg/L화(86.72±35.26)μmmol/L、(6.61±3.09 )mmol/L、(1.29±0.29)mg/L우우대조조(129.22±50.18)μmmol/L、(9.26±3.95) mmol/L、(1.56±0.23)mg/L화(109.83±31.76)μmmol/L、(8.07±3.11)mmol/L、(1.37±0.21)mg/L,차이유통계학의의(균P＜0.05).경직선상관분석,조영제제량여BUN、Scr정현저정상관(r=0.74,P＜0.05; r=0.82,P＜0.01).결론 PGE1대관심병합병당뇨병적환자발생조영제신병유예방작용.
Objective To study whether prostaglandin E1 (LipoPGE1) could prevent contrast medium-induced nephropathy (CIN) in patients with coronary heart disease (CHD) plus diabetes mellitus type 2 (DM).Methods Total 198 CHD patients with DM received coronary angiography (CAG) or PCI were randomly divided into PGE1 group and control group.All patients received routine treatment,and the PGE1 group also received 20 ml normal saline and 20 μg PGE1 (intravenous injection,1 time/d) for 10 days.The rate of CIN and the level of serum urea nitrogen (BUN),creatinine (Scr),cystatin C (Cys C) were measured before and 48 hours and 5 days after contrastmedium administration.Results The level of Scr,BUN and Cys C were lower in PGE1 group [(113.92±54.89)μmmol/ L,(7.85±4.05)mmol/L,(1.38±0.34)mg/L]for 48 hours and[(86.72±35.26)μmmol/L,(6.61 ± 3.09 ) mmol/L,( 1.29 ± 0.29) mg/L]for 5 days than in control group [(129.22±50.18)μmmol/L,(9.26±3.95)mmol/L,(1.56±0.23)mg/L]for 48 hours and[(109.83+31.76)μmmol/ L,(8.07±3.11)mmol/L,(1.37±0.21)mg/L]for 5 days (all P＜0.05).The dose of contrast-medium was positively correlated with the level of Scr and BUN (r=0.74,P＜0.05 and r =0.82,P＜0.01,respectively).The patients' renal function in the PGE1 group was better than in control group after contrast-medium administration (P ＜0.05).BUN and Scr were positively correlated with the volume of contrast-medium (r=0.74,P＜0.05,r=0.82,P＜0.01).Conclusions PGE1 may prevent contrast medium-induced nephropathy in patients with CHD combined with DM.
